Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

Abstract

After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were either missing or incorrectly indicated as contributing author while in fact they didn't contribute in the following abstracts. In addition affiliations were listed where in fact there were no contributing authors affiliated with them in the following abstracts. This has now been included in this correction.

cGAS-STING, an important pathway in cancer immunotherapy

“…The anti-tumor compound dithio CDN (ML RR-S2 CDN, also known as ADU-S100 or MIW815) showed a high binding affinity to hSTING alleles [41]. This CDN analog showed marked antitumor efficacy in various cancer mouse models, which made it become the first STING agonist entering clinical trials in advanced metastatic solid tumors or lymphomas, with the first results reported in 2018, at the Society for ImmunoTherapy of Cancer meeting [47]. The inclusion criteria included 18-years old or older patients with advanced/ metastasis solid tumors or lymphomas, Eastern Cooperative Oncology Group performance status of 0-1, and two or more cutaneous or subcutaneous neoplastic lesions accessible for biopsy, with one that could be injected.…”

“…This phase I study enrolled 41 patients heavily pretreated before: 3 (7.3%) patients had received at least one prior-line treatment, 34 (82.9%) patients had received at least two prior treatments, and 22 (53.7%) had exposed to the ICIs therapy prior. During treatment, 35 of them discontinued because of disease progression (n = 26), physician or patient decision (n = 8), and death (n = 1) [47]. Dose-limiting toxicities were not reported, and the common adverse events were mainly including pyrexia, pain at the injection site, and headache.…”

Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy

“…In fact, the occurrence of true ICI-induced hyperprogression has been questioned altogether, as the accelerated tumor growth could be the result of factors intrinsic to the tumor itself which would lead to rapid growth over time even without the initiation of ICI ( 16 ). To this end, recent communication from Bristol Meyer Squibb highlights data from their CheckMate 451 and ATTRACTION-2 clinical trials which show that hyperprogression can be found at similar incidence in both placebo and ICI-treated patients ( 17 , 18 ).…”

The cGAS/STING Pathway: A Novel Target for Cancer Therapy

“…During peritoneal metastasis, type I IFN signaling also inhibited the recruitment of CD206 + M2-like macrophages ( 84 ). Notably, the intratumoral injection of ADU-S100 was shown to be well-tolerated in patients with advanced solid tumors and lymphomas, and no DLT was reported ( 85 ). IACS-8779 and IACS-8803 are highly efficient CDN STING agonists that introduce a group of reasonably selected and targeted modifications into the nucleobase and ribose sections of the 2’,3’ CDA structure.…”